952664-65-2

Basic information

• Product Name: 1-(3,4-dihydroxyphenyl)cyclopropanecarboxylic methyl ester
• Synonyms: 1-(3,4-dihydroxyphenyl)cyclopropanecarboxylic methyl ester
• CAS NO: 952664-65-2
• Molecular Weight: 208.214
• Mol File: 952664-65-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-(3,4-dihydroxyphenyl)cyclopropanecarboxylic methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,4-dihydroxyphenyl)cyclopropanecarboxylic methyl ester(952664-65-2)
• EPA Substance Registry System: 1-(3,4-dihydroxyphenyl)cyclopropanecarboxylic methyl ester(952664-65-2)

Safety Data

• Hazardous Substances Data: 952664-65-2(Hazardous Substances Data)

Upstream product

• 459453-60-2 3,4-dimethoxybenzeneacrylic acid methyl ester 
• 15964-79-1 methyl (3,4-dimethoxyphenyl)acetate 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 
• 104-15-4 toluene-4-sulfonic acid 
• 1699-60-1 (3,4-bis-benzyloxyphenyl)acetonitrile 
• 67-56-1 methanol 
• 952664-49-2 1-(3,4-dihydroxyphenyl)cyclopropanecarbonitrile 
• 952664-48-1 1-(3,4-bis-benzyloxyphenyl)cyclopropanecarbonitrile 

Relevant articles and documents

1 - (2, 2 - Difluorobenzene and [d] [1, 3] dioxo heterocyclic pentene - 5 - yl) cyclopropanecarboxylic acid synthetic method and intermediate

The invention belongs to the field of chemical synthesis of drugs, particularly relates to a synthetic method of 1-(2,2-difluoro-benzo[d][1,3]) dioxole-5-yl) cyclopropanecarboxylic acid and an intermediate and aims to provide a synthesis method of a compound (1). The method comprises steps as follows: a, a compound (4) and boron tribromide react, and a compound (3) is synthesized; b, the compound (3) and difluorodibromomethane have a ring closing reaction in the presence of a phase-transfer catalyst, and a compound (2) is synthesized; c, the compound (2) is hydrolyzed, and the compound (1) is synthesized. According to the synthetic method and the intermediate, one novel compound (4) is provided, one novel preparation method of the compound (1) is obtained, with the adoption of the method, not only can the overall yield of the reaction be increased, but also expensive reaction raw materials can be avoided, and the reaction cost is reduced to the great extent; besides, according to the method, utilization of a palladium catalyst and a dangerous sodium cyanide reagent can further be avoided, the safety of pharmaceutical production is guaranteed, and the method is applicable to industrial production.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.